A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis
Abstract Theranostics is a way of treating illness that blends medicine with testing. Specific characteristics should be present in the best theranostic agents for cancer: (1) the drugs should be safe and non-toxic; (2) they should be able to treat cancer selectively; and (3) they should be able to...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-024-03610-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571299414671360 |
|---|---|
| author | Hannaneh Azimizonuzi Arman Ghayourvahdat Mareb Hamed Ahmed Radhwan Abdul Kareem Athmar Jaber Zrzor Aseel Salah Mansoor Zainab H. Athab Shaylan Kalavi |
| author_facet | Hannaneh Azimizonuzi Arman Ghayourvahdat Mareb Hamed Ahmed Radhwan Abdul Kareem Athmar Jaber Zrzor Aseel Salah Mansoor Zainab H. Athab Shaylan Kalavi |
| author_sort | Hannaneh Azimizonuzi |
| collection | DOAJ |
| description | Abstract Theranostics is a way of treating illness that blends medicine with testing. Specific characteristics should be present in the best theranostic agents for cancer: (1) the drugs should be safe and non-toxic; (2) they should be able to treat cancer selectively; and (3) they should be able to build up only in the cancerous tissue. Liposomes (LPs) are one of the most efficient drug delivery methods based on nanotechnology. Stealth LPs and commercial LPs have recently had an impact on cancer treatment. Using the valuable information from each imaging technique, along with the multimodality imaging functionality of liposomal therapeutic agents, makes them very appealing for personalized monitoring of how well therapeutic drugs are working against cancer in vivo and for predicting how well therapies will work. On the other hand, their use as nanoparticle delivery systems is currently in the research and development phase. Nanoscale delivery system innovation has made LP-nanoparticle hybrid structures very useful for combining therapeutic and imaging methods. LP-hybrid nanoparticles are better at killing cancer cells than their LP counterparts, making them excellent options for in vivo and in vitro drug delivery applications. Hybrid liposomes (HLs) could be used in the future as theranostic carriers to find and treat cancer targets. This would combine the best features of synthetic and biological drug delivery systems. Overarchingly, this article provided a comprehensive overview of the many LP types used in cancer detection, therapy, and theranostic analysis. An evaluation of the pros and cons of the many HLs types used in cancer detection and treatment has also been conducted. The study also included recent and significant research on HLs for cancer theranostic applications. We conclude by outlining the potential benefits and drawbacks of this theranostic approach to the concurrent detection and treatment of different malignancies, as well as its prospects. Graphical Abstract |
| format | Article |
| id | doaj-art-4b85345634ae4325a962670fc3430713 |
| institution | Kabale University |
| issn | 1475-2867 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj-art-4b85345634ae4325a962670fc34307132025-02-02T12:43:23ZengBMCCancer Cell International1475-28672025-01-0125116410.1186/s12935-024-03610-zA state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosisHannaneh Azimizonuzi0Arman Ghayourvahdat1Mareb Hamed Ahmed2Radhwan Abdul Kareem3Athmar Jaber Zrzor4Aseel Salah Mansoor5Zainab H. Athab6Shaylan Kalavi7Inventor Member of International Federation of Inventors AssociationsInventor Member of International Federation of Inventors AssociationsCollege of Dentistry, Alnoor UniversityAhl Al Bayt UniversityCollage of Pharmacy, National University of Science and TechnologyGilgamesh Ahliya UniversityDepartment of Pharmacy, Al-Zahrawi University CollegeDepartment of Clinical Pharmacy, Faculty of Pharmacy, Islamic Azad University of Medical SciencesAbstract Theranostics is a way of treating illness that blends medicine with testing. Specific characteristics should be present in the best theranostic agents for cancer: (1) the drugs should be safe and non-toxic; (2) they should be able to treat cancer selectively; and (3) they should be able to build up only in the cancerous tissue. Liposomes (LPs) are one of the most efficient drug delivery methods based on nanotechnology. Stealth LPs and commercial LPs have recently had an impact on cancer treatment. Using the valuable information from each imaging technique, along with the multimodality imaging functionality of liposomal therapeutic agents, makes them very appealing for personalized monitoring of how well therapeutic drugs are working against cancer in vivo and for predicting how well therapies will work. On the other hand, their use as nanoparticle delivery systems is currently in the research and development phase. Nanoscale delivery system innovation has made LP-nanoparticle hybrid structures very useful for combining therapeutic and imaging methods. LP-hybrid nanoparticles are better at killing cancer cells than their LP counterparts, making them excellent options for in vivo and in vitro drug delivery applications. Hybrid liposomes (HLs) could be used in the future as theranostic carriers to find and treat cancer targets. This would combine the best features of synthetic and biological drug delivery systems. Overarchingly, this article provided a comprehensive overview of the many LP types used in cancer detection, therapy, and theranostic analysis. An evaluation of the pros and cons of the many HLs types used in cancer detection and treatment has also been conducted. The study also included recent and significant research on HLs for cancer theranostic applications. We conclude by outlining the potential benefits and drawbacks of this theranostic approach to the concurrent detection and treatment of different malignancies, as well as its prospects. Graphical Abstracthttps://doi.org/10.1186/s12935-024-03610-zLiposome hybridsCancerTheranosticDetectionTreatment |
| spellingShingle | Hannaneh Azimizonuzi Arman Ghayourvahdat Mareb Hamed Ahmed Radhwan Abdul Kareem Athmar Jaber Zrzor Aseel Salah Mansoor Zainab H. Athab Shaylan Kalavi A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis Cancer Cell International Liposome hybrids Cancer Theranostic Detection Treatment |
| title | A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis |
| title_full | A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis |
| title_fullStr | A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis |
| title_full_unstemmed | A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis |
| title_short | A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis |
| title_sort | state of the art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis |
| topic | Liposome hybrids Cancer Theranostic Detection Treatment |
| url | https://doi.org/10.1186/s12935-024-03610-z |
| work_keys_str_mv | AT hannanehazimizonuzi astateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT armanghayourvahdat astateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT marebhamedahmed astateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT radhwanabdulkareem astateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT athmarjaberzrzor astateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT aseelsalahmansoor astateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT zainabhathab astateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT shaylankalavi astateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT hannanehazimizonuzi stateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT armanghayourvahdat stateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT marebhamedahmed stateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT radhwanabdulkareem stateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT athmarjaberzrzor stateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT aseelsalahmansoor stateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT zainabhathab stateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis AT shaylankalavi stateoftheartreviewoftherecentadvancesoftheranosticliposomehybridnanoparticlesincancertreatmentanddiagnosis |